Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
stocks
Bookworm: Is this the secret to exceptional long-term returns?
stocks
Unconventional wisdom: Are dividends the answers?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,963.50 | 29.20 | 0.33% |
CAC 40 | 7,925.54 | 90.96 | 1.16% |
DAX 40 | 24,436.09 | 218.59 | 0.90% |
Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
FTSE 100 | 9,164.85 | 44.54 | 0.49% |
HKSE | 25,588.18 | 199.83 | 0.79% |
NASDAQ | 21,108.32 | 50.36 | 0.24% |
Nikkei 225 | 40,998.27 | 457.96 | -1.10% |
NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
S&P 500 | 6,388.64 | 25.29 | 0.40% |
S&P/ASX 200 | 8,697.70 | 30.80 | 0.36% |
SSE Composite Index | 3,597.94 | 4.28 | 0.12% |